109 related articles for article (PubMed ID: 8388560)
1. [Cost-effectiveness of the prevention of postoperative thromboembolism].
Bergqvist D; Mätzsch T
Orthopade; 1993 Apr; 22(2):140-3. PubMed ID: 8388560
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients.
McGarry LJ; Thompson D; Weinstein MC; Goldhaber SZ
Am J Manag Care; 2004 Sep; 10(9):632-42. PubMed ID: 15515996
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of prevention of post-operative thromboembolism.
Bergqvist D; Mätzsch T; Jendteg S; Lindgren B; Persson U
Acta Chir Scand Suppl; 1990; 556():36-41. PubMed ID: 2126903
[TBL] [Abstract][Full Text] [Related]
4. Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review.
Huo MH; Muntz J
Clin Ther; 2009 Jun; 31(6):1129-41. PubMed ID: 19695383
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis.
Rodger M; Bredeson C; Wells PS; Beck J; Kearns B; Huebsch LB
CMAJ; 1998 Oct; 159(8):931-8. PubMed ID: 9834718
[TBL] [Abstract][Full Text] [Related]
6. Low molecular weight heparin for the prevention and treatment of venous thromboembolism.
Raskob GE
Curr Opin Pulm Med; 1996 Jul; 2(4):305-10. PubMed ID: 9363157
[TBL] [Abstract][Full Text] [Related]
7. Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective.
Hull RD; Raskob GE; Rosenbloom D; Pineo GF; Lerner RG; Gafni A; Trowbridge AA; Elliott CG; Green D; Feinglass J
Arch Intern Med; 1997 Feb; 157(3):289-94. PubMed ID: 9040295
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective.
Hull RD; Raskob GE; Pineo GF; Feldstein W; Rosenbloom D; Gafni A; Green D; Feinglass J; Trowbridge AA; Elliott CG
Arch Intern Med; 1997 Feb; 157(3):298-303. PubMed ID: 9040296
[TBL] [Abstract][Full Text] [Related]
9. [Prophylaxis of venous thrombosis, yes but...].
Korin JD; Sánchez Avalos JC
Medicina (B Aires); 1996; 56(3):299-307. PubMed ID: 9035489
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of prophylactic low molecular weight heparin in pregnant women with a prior history of venous thromboembolism.
Johnston JA; Brill-Edwards P; Ginsberg JS; Pauker SG; Eckman MH
Am J Med; 2005 May; 118(5):503-14. PubMed ID: 15866253
[TBL] [Abstract][Full Text] [Related]
11. [Therapy of thromboses with low-molecular-weight heparins].
Haas S; Haas P
Wien Med Wochenschr; 1999; 149(2-4):39-45; discussion 45. PubMed ID: 10378321
[TBL] [Abstract][Full Text] [Related]
12. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
Haentjens P; De Groote K; Annemans L
Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
[TBL] [Abstract][Full Text] [Related]
13. The use of low molecular weight heparins for the prevention of postoperative venous thromboembolism in general surgery. A survey of practice in the United States.
Caprini JA; Arcelus J; Sehgal LR; Cohen EB; Reyna JJ
Int Angiol; 2002 Mar; 21(1):78-85. PubMed ID: 11941278
[TBL] [Abstract][Full Text] [Related]
14. [The prophylaxis against venous thromboembolic complications in internal medicine--the gap between theory and practice].
Hirmerová J
Vnitr Lek; 2006 Apr; 52(4):379-88. PubMed ID: 16755994
[TBL] [Abstract][Full Text] [Related]
15. Should low-molecular-weight heparins replace unfractionated heparin as the agent of choice for adults with deep venous thrombosis?
Brewer D
J Fam Pract; 1998 Sep; 47(3):185-92. PubMed ID: 9752370
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery.
Mismetti P; Laporte S; Darmon JY; Buchmüller A; Decousus H
Br J Surg; 2001 Jul; 88(7):913-30. PubMed ID: 11442521
[TBL] [Abstract][Full Text] [Related]
17. [Heparin therapy: 1998 (current use of the 80-year-old heparin)].
Rák K
Orv Hetil; 1999 Jan; 140(2):59-66. PubMed ID: 9949661
[TBL] [Abstract][Full Text] [Related]
18. A review of the risks and benefits of differing prophylaxis regimens for the treatment of deep venous thrombosis and pulmonary embolism in neurosurgery.
Epstein NE
Surg Neurol; 2005 Oct; 64(4):295-301; discussion 302. PubMed ID: 16181995
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary embolism in medical patients: improved diagnosis and the role of low-molecular-weight heparin in prevention and treatment.
Merli GJ
J Thromb Thrombolysis; 2004 Oct; 18(2):117-25. PubMed ID: 15789178
[TBL] [Abstract][Full Text] [Related]
20. The rationale for long-term prophylaxis of venous thromboembolism.
Agnelli G; Mancini GB; Biagini D
Orthopedics; 2000 Jun; 23(6 Suppl):s643-6. PubMed ID: 10875429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
